Search results
Michael Rosenblatt, M.D., is a Senior Advisor at Flagship Pioneering and serves as an independent director on a number of Flagship company boards and provides guidance to Flagship and Flagship companies.
Michael Rosenblatt, MD ’73. Senior Advisor, Ascenta Capital; Senior Advisor, Bain Capital Life Sciences; Senior Advisor, Flagship Pioneering.
Michael Rosenblatt, M.D., has held major leadership roles in academia and the biopharmaceutical industry, and currently serves as Senior Partner of Flagship Pioneering in Cambridge, MA. Dr. Rosenblatt was Chief Medical Officer (CMO) for Merck from 2009-2016.
Dr. Rosenblatt is a physician, scientist, educator and leader in healthcare. He has worked in academia, pharmaceutical industry and biotech/venture, and served as Dean, CMO, and board member of several organizations.
Sep 29, 2016 · Michael Rosenblatt, newly appointed Chief Medical Officer of Flagship Ventures and former Chief Medical Officer at Merck & Co., discusses his move from industry to venture capital.
Jul 13, 2016 · Dr. Rosenblatt was named Senior Vice President for Research at Merck, Sharpe & Dohme Research Laboratories in 1984, and spent nearly a decade at Merck, co-leading the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders.
Michael Rosenblatt is Ebert Professor of Molecular Medicine, Harvard Medical School, and former Co-Director of the Harvard-MIT Division of Health Sciences and Technology.
